
Oncology NEWS International
- Oncology NEWS International Vol 18 No 6
- Volume 18
- Issue 6
ALK-1 receptor: New target in angiogenesis
Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).
Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).
Articles in this issue
almost 17 years ago
ADT in prostate ca increases risk of bone and heart complicationsalmost 17 years ago
Abraxis backs SPARC as prognostic biomarkeralmost 17 years ago
Abraxane prolongs PFS in metastatic diseasealmost 17 years ago
SAVI applicator removes obstacles associated with brachytherapyalmost 17 years ago
Mistrust, costs reduce breast cancer screening among minoritiesalmost 17 years ago
Oral chemotherapy poses more challenges for cancer communityalmost 17 years ago
CMS nixes CT colonography screeningalmost 17 years ago
New ultrasound strategy helps pinpoint prostate tumorsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.























































